Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06381648 · ClinicalTrials.gov registry record
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
A clinical trial of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 230
- Enrollment target
- 4
- Study locations
NCT06381648: Completed study of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic, sponsored by City of Hope Medical Center.
NCT06381648 is a study of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic that has completed, run by City of Hope Medical Center. The registered enrollment target is 230 participants, below the 382-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (40% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06381648, a study of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 230 participants
- Enrollment target
- 4
- Study locations
Study Summary
Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.
Primary Outcome
True Positive Rate: the probability of a positive test result, conditioned on the individual truly being positive
Conditions Studied
Interventions
- DIAGNOSTIC_TEST LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Study Locations (4)
Other
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University - Fukuoka
- Department of Surgery, Tokushima University - Tokushima
California
- City of Hope Medical Center - Duarte
Sapporo
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University - Hokkaido
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-04-15 |
| Est. Completion | 2025-07-01 |
What the finished NCT06381648 record still lists
NCT06381648 is an observational study that tracks outcomes without assigning an intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 382-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (40% lower).
The record links to 4 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma) is the first listed.
NCT06381648 reports a single indexed study location in Other, California, Sapporo.
Frequently Asked Questions
What is clinical trial NCT06381648 about?
NCT06381648 is a clinical study titled "Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)". Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers ...
What is the current status of trial NCT06381648?
This trial is currently completed. The enrollment target is 230 participants. The study started on 2023-04-15. Estimated completion is 2025-07-01.
What conditions does trial NCT06381648 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Resectable, Cholangiocarcinoma; Liver.
What interventions are being tested in trial NCT06381648?
The interventions under investigation include: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06381648?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06381648 being conducted?
This trial has 4 study locations across California, Sapporo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06381648's enrollment target sits among peer trials
230 18th of 60 higher than 43 of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI